----item----
version: 1
id: {FDFC75C6-AE8D-496B-8780-D9FBDB94F7E2}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/05/22/Is Cellectis Pfizers latest target
parent: {F5E96EB9-60E0-4AAE-863A-DF3CFDF656A2}
name: Is Cellectis Pfizers latest target
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 0303f776-e65c-47b3-a178-3bf487726faa

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 155

{3B33748A-17E9-4241-8447-989BB3484DFB}|{CD796374-A60A-4D81-8A05-7B92AD2013C1}|{3FA7743D-5DAB-49A3-B30D-DF5079ADB082}|{C73EC67A-5E68-4D6E-8A63-F12AB8D18B20}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 36

Is Cellectis Pfizer's latest target?
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 34

Is Cellectis Pfizers latest target
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 2580

<p>Rumors that Pfizer is circling yet another European acquisition target have pushed French biotech Cellectis's stock up to an all-time high on Nasdaq.</p><p>Cellectis provided a standard "no comment" response to queries from <i>Scrip</i> regarding supposed takeover talks with the US pharma giant but articles citing "people in the know" have caused a stir. </p><p>Various news sites, on the back of a <i>Financial Times</i> article, are reporting that Pfizer has approached Cellectis with an offer valuing the company at as much as &euro;1.5bn (approximately $1.6bn).</p><p>As a result Cellectis's stock closed up by36% at $47.66 per share on 28 May on Nasdaq, where the company only listed in March. On the Paris Stock Exchange shares of the company opened up at &euro;40 per share on 29 May &ndash; its highest price since late March. </p><p>If the rumors play out, an acquisition of Cellectis would strengthen Pfizer's immune-oncology portfolio and mark the US firm's second big takeover this year. <a href="http://www.scripintelligence.com/home/Wheres-the-value-in-Pfizers-17bn-Hospira-buy-356578" target="_new">In February</a> Pfizer paid $17bn for sterile injectable drug maker Hospira. </p><p>Pfizer acquired a 9.5% stake in Cellectis when the two companies linked up on a collaboration to develop cancer immunotherapies <a href="http://www.scripintelligence.com/home/Cellectis-soars-as-Pfizer-fronts-80m-for-immuno-oncology-352405" target="_new">last year</a>. Pfizer struck the deal &ndash; paying $80m upfront to the French biotech &ndash; for access to its Chimeric Antigen Receptor T-cell (CAR-T) technology. Under the deal both companies have jointly been working on preclinical research for 15 targets selected by Pfizer and four targets chosen by Cellectis.</p><p>All eyes have been on Pfizer for a big takeover offer since the pharma major failed to acquire AstraZeneca in 2014. <a href="http://www.scripintelligence.com/home/comment/Follow-the-numbers-could-Pfizer-bid-for-GSK-358416" target="_new">Two weeks ago</a>, in a <i>Biospace</i> poll, GlaxoSmithKline was deemed the most likely target in a deal estimated to reach $120bn. </p><p>Also during the company's <a href="http://www.scripintelligence.com/home/Major-acquisition-still-on-the-table-for-Pfizer-in-2015-358097" target="_new">first quarter results</a> presentation in April CEO Ian Read said Pfizer "has the capability of undertaking other deals." He said then that the company is "agnostic" to the size of any acquisition as long as it "moved the needle" and created value for shareholders. </p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 156

<p>Rumors that Pfizer is circling yet another European acquisition target have pushed French biotech Cellectis's stock up to an all-time high on Nasdaq.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 34

Is Cellectis Pfizers latest target
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150522T160000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150522T160000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150522T160000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028864
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 36

Is Cellectis Pfizer's latest target?
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

199902692
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{090E9A04-9B4B-4986-8BAF-06A6B07B978D}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

358565
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042353Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

0303f776-e65c-47b3-a178-3bf487726faa
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042353Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
